for 24/7 on-call assistance
This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and may be subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
Coding and billing for CAR T cell therapies will vary based on the patient’s condition, provided services, payer-specific requirements, and selected site/setting of care. It is critical for treatment centers to confirm specific payer requirements prior to claim submission in order to avoid processing delays or denials.
HCPCS Level II Codes |
|
Hospital Revenue Codes |
|
ICD-10-PCS Codes |
|
CPT® Codes* |
|
Medicare Fee-for-Service (FFS) |
|
Medicare Advantage (MA) Plans | Starting in January 2021 (CAR T cell therapy is paid by MA plans):
|
Commercial Plans and Other Payers |
|
*CPT codes, descriptions, and other data only are copyright 2021 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply.
Visit the Resource Library for informative downloadable tools.
CMS=Centers for Medicare and Medicaid Services; CPT=Current Procedural Terminology; FARS/HHSARS=financial assistance reporting system/health and human services acquisition regulations; HCPCS=Healthcare Common Procedure Coding System; ICD-10-PCS=International Classification of Diseases, Tenth Revision, Procedure Coding System.
For product-specific resources, click here.
CAR=chimeric antigen receptor.
This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and may be subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
You are now entering the Cell Therapy 360® Scheduling and Apheresis Portal.
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
You are now leaving this Bristol Myers Squibb site.
This internet site may provide links or references to other sites. BMS has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.
Are you sure you want to leave the enrollment section?
Your work will not be saved until you fill out the Patient Authorization and Consent page and submit your part of the enrollment form.
It won’t take long!
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Please confirm your patient’s diagnosis:
Please confirm that you are a:
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Select a disease state:
R/R=relapsed/refractory.
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Insurance coverage information is currently available for R/R large B-cell lymphoma only.
R/R=relapsed/refractory.
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Please confirm your patient’s diagnosis:
R/R=relapsed/refractory.